# A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

> **NCT06897813** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhejiang Wenda Pharma Technology LTD.** · enrollment: 68 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** WD-910 tablet
- **DRUG:** WD-910 Tablets Placebo

## Key facts

- **NCT ID:** NCT06897813
- **Lead sponsor:** Zhejiang Wenda Pharma Technology LTD.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06897813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06897813, "A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06897813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*